For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
The rabbit immune system is complex and generates highly sensitive antibodies. Due to their superior antigen recognition, antibodies that are difficult to make in mice can often be produced in rabbits (1, 2).
The need to generate rabbit monoclonal antibodies was addressed 20 years ago, as polyclonals have the drawback of inconsistent signal quality (i.e. non-specificity, high background). In contrast, monoclonals offer unique epitope recognition, lot-to-lot consistency and sustainable supply.
“With increasing demands from scientific communities and healthcare industries for antibodies with better sensitivity and specificity, rabbit monoclonals were the answer.”
Weimin Zhu, Co-inventor of RabMAb® technology, Abcam –
Many attempts were made to generate rabbit monoclonal antibodies following the development of mouse hybridoma technology, where myeloma cells were fused with mouse spleen cells (3).
The first of these were mouse-rabbit heterohybridomas, which were not ideal as they were difficult to clone, unstable and had a somewhat limited production source. (4).
In 1995, Katherine Knight and her colleagues at Loyola University of Chicago developed a double transgenic rabbit that over-expressed the oncogenes v-abl and c-myc. These were under the control of the immunoglobulin heavy and light chain enhancers, and the rabbit formed a myeloma-like tumor.
This enabled the the isolation of a plasmacytoma cell line, named 240E-1, the first fusion partner to generate rabbit monoclonals. Fusion of 240E-1 cells with rabbit lymphocytes produced hybridomas that secreted rabbit monoclonal antibodies in a consistent manner, but the stability of the fusion partner was a concern (5).
At the University of California San Francisco in 1996, Weimin Zhu and Robert Pytela obtained 240E-1 from Dr. Knight’s laboratory and developed the technology further (6).
240E-1 cells were repeatedly subcloned and selected to improve the characteristics of the fusion line. Selection criteria included fusion efficiency, growth, and morphological characteristics (i.e. bright appearance under a phase contrast microscope).
Selected subclones were further analysed to ensure they produced stable hybridomas and effeciently secreted monoclonal antibodies. After multiple rounds of subcloning, a new cell line named 240E-W was generated that showed greater fusion efficiency and stability.
This was followed by the development of RabMAb technology, Abcam's patented technology to develop highly specific monoclonal antibodies with high sensitivity.
Cell line 240E-W has since been further modified to eliminate endogenous IgG issues. Since 2006, the new fusion partner (240E-W2, a core part of the RabMAb technology as we know it today), has been used for production of rabbit monoclonal antibodies for both research and commercial applications.
RabMAb technology makes it possible to develop high quality monoclonal antibodies for research, diagnostic and therapeutic applications. In the past 16 years, RabMAb technology has proven to be the premium technology to fulfill various needs within the scientific community.